Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer’s disease: impact on non Alzheimer’s dementia?

  • N. Rösler
  • I. Wichart
  • C. Bancher
  • K. A. Jellinger
Part of the Journal of Neural Transmission Supplement book series (NEURAL SUPPL, volume 47)


Tau protein and apolipoprotein E are suggested to be biochemically related to neurofibrillary tangles and senile plaques in Alzheimer’s disease (AD) brains. They can be detected as immunoreactive material (total tau immunoreactivity [TTIR] and apolipoprotein E-immunoreactivity [ApoEIR]) in the cerebrospinal fluid (CSF).

TTIR and ApoE-IR have been measured in ex vivo lumbar and post mortem ventricular CSF in AD, other neurological diseases without cognitive impairment, elderly depressive patients, and young and elderly controls.

In lumbar CSF, there was a highly significant increase of TTIR and a minor, insignificant decrease of ApoE-IR in CSF of AD patients. The latter result was also found in ventricular CSF, whereas TTIR showed no significant difference between groups in the rostral CSF compartment.

As depressive periods in the elderly may mimick a dementing process, these findings contribute to the differential diagnosis of these disorders by showing a different neurobiochemical CSF profile. Work in progress will include a variety of non-Alzheimer’s dementias and possibly will further increase the value of CSF investigation in neurodegenerative disorders.


Mini Mental Status Examination Neurofibrillary Tangle Mini Mental Status Examination Score ApoE Level Paired Helical Filament 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM (1989) Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res 477: 90–99PubMedCrossRefGoogle Scholar
  2. Blennow K, Hesse C, Fredman P (1994) Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer’s disease. NeuroReport 5: 2534–2536Google Scholar
  3. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82: 306–315CrossRefGoogle Scholar
  4. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D (1991) Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta 196: 167–176Google Scholar
  5. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ (1994) Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol 51: 888–895PubMedCrossRefGoogle Scholar
  6. Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 16: 460–465PubMedCrossRefGoogle Scholar
  7. Hock C, Golombowski S, Naser W, Müller-Spahn F (1995) Increased levels of tau-protein in cerebrospinal fluid of patients with Alzheimer’s disease-correlation with degree of cognitive impairment. Ann Neurol 37: 414–415PubMedCrossRefGoogle Scholar
  8. Jellinger K, Danielczyk W, Fischer P, Gabriel E (1990) Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 95: 239–258PubMedCrossRefGoogle Scholar
  9. Jellinger K, Bancher C, Fischer P, Lassmann H (1992) Quantitative histopathologic validation of senile dementia of the Alzheimer type. Eur J Gerontol 3: 146–156Google Scholar
  10. Khachaturian Z (1985) Diagnosis of Alzheimer’s disease. Arch Neurol 42: 1097–1105PubMedCrossRefGoogle Scholar
  11. Martinoli MG, Trojanowski JQ, Schmidt ML, Arnold SE, Fujiwara TM, Lee VMY, Hurtig H, Julien JP, Clark C (1995) Association of apolipoprotein e4 allele and neuropathologic findings in patients with dementia. Acta Neuropathol 90: 239–243PubMedCrossRefGoogle Scholar
  12. Mercken M, Vandermeeren M, Lübcke U, Six J, Boons J, Vanmechelen E, Van de Voorde A, Gheuens J (1992) Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem 58: 548–553PubMedCrossRefGoogle Scholar
  13. Namba Y, Tomanaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541: 163–166Google Scholar
  14. Poirier J (1994) Apolipoprotein E in animals models of CNS injury and in Alzheimer’s disease. Trends Neurosci 17: 525–530Google Scholar
  15. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high avidity binding to 13-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977–1981PubMedCrossRefGoogle Scholar
  16. Tato RE, Frank A, Hernanz A (1995) Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 59: 280–283PubMedCrossRefGoogle Scholar
  17. Tierney MC, Fisher RW, Lewis AJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstraten P (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease. A clinico-pathologic study of 57 cases. Neurology 38: 359–364PubMedGoogle Scholar
  18. Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin JJ, Cras P (1993) Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61: 1828–1834PubMedCrossRefGoogle Scholar
  19. Van de Voorde A, Vanmechelen E, Vandermeeren M, Dessaint F, Beckman W, Cras P (1995) Detection of tau in cerebrospinal fluid. In: Iqbal K, Mortimer JA, Winblad W, Wisniewski HM (eds) Research advances in Alzheimer’s disease and related disorders. Wiley, Chichester, pp 189–195Google Scholar
  20. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135: 235–238PubMedCrossRefGoogle Scholar
  21. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B (1993) Apolipoprotein E: binding to soluble Alzheimer’s 13-amyloid. Biochem Biophys Res Commun 192: 359–365PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • N. Rösler
    • 1
  • I. Wichart
    • 1
  • C. Bancher
    • 1
  • K. A. Jellinger
    • 1
  1. 1.Ludwig Boltzmann-Institut für klinische NeurobiologieKrankenhaus Wien-LainzWienAustria

Personalised recommendations